SCYNEXIS, Inc. (SCYX) vs Talphera, Inc. (TLPH)

SCYNEXIS, Inc. and Talphera, Inc. are both Drug Manufacturers Specialty & Generic companies. Talphera, Inc. is the larger, with a market value of $60.7M against $45.0M — 1.4× the size. SCYNEXIS, Inc. grew revenue faster over the last twelve months: 682.5% against −73.1%. Talphera, Inc. has the higher net margin (0.00% vs −49.7%) and the higher return on invested capital (0.00% vs −110.7%). Across the 16 metrics below, SCYNEXIS, Inc. leads on 9 and Talphera, Inc. on 7.

Valuation

Metric SCYX TLPH Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 2.52 209.21 2.25
P/B 0.78 6.19 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 1.15 183.86 2.56
Earnings yield (47.61%) (22.88%) (2.99%)
Free cash flow yield (25.67%) (10.82%) 0.00%

Profitability

Metric SCYX TLPH Drug Manufacturers Specialty & Generic median
Gross margin 100.00% 100.00% 53.94%
Operating margin (109.90%) 0.00% 0.00%
Net margin (49.74%) 0.00% 0.00%
Free cash flow margin (64.67%) 0.00% 0.00%
Return on equity (18.38%) (143.36%) (0.40%)
Return on assets (15.09%) (69.60%) (3.32%)
Return on invested capital (110.72%) 0.00% 0.00%

Growth

Metric SCYX TLPH Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 682.47% (73.07%) 10.01%
EPS growth (last fiscal year) 61.36% 32.00% —
Revenue growth, 5-year CAGR 179.40% (58.55%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SCYX TLPH Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.05
Current ratio 9.65 4.29 2.31
Net debt to EBITDA 2.54 1.50 0.85

Dividend

Metric SCYX TLPH Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric SCYX TLPH Drug Manufacturers Specialty & Generic median
Market cap 44.98m 60.73m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack